PD GBA Glucocerebrosidase Therapeutic Companies

📖 Wiki Page

company780 wordssynced 2026-04-02

Overview

flowchart TD companies_pd_gba_companies["PD GBA Glucocerebrosidase Therapeutic Companies"] style companies_pd_gba_companies fill:#4fc3f7,stroke:#333,color:#000 companies_pd_gba_com_0["Key Companies"] companies_pd_gba_companies -->|"includes"| companies_pd_gba_com_0 style companies_pd_gba_com_0 fill:#81c784,stroke:#333,color:#000 companies_pd_gba_com_1["Gene Therapy Approaches"] companies_pd_gba_companies -->|"includes"| companies_pd_gba_com_1 style companies_pd_gba_com_1 fill:#ef5350,stroke:#333,color:#000 companies_pd_gba_com_2["Molecular Chaperone Therapy"] companies_pd_gba_companies -->|"includes"| companies_pd_gba_com_2 style companies_pd_gba_com_2 fill:#ffd54f,stroke:#333,color:#000 companies_pd_gba_com_3["Substrate Reduction Therapy"] companies_pd_gba_companies -->|"includes"| companies_pd_gba_com_3 style companies_pd_gba_com_3 fill:#ce93d8,stroke:#333,color:#000 companies_pd_gba_com_4["Lysosomal Enhancement Approaches"] companies_pd_gba_companies -->|"includes"| companies_pd_gba_com_4 style companies_pd_gba_com_4 fill:#4fc3f7,stroke:#333,color:#000 companies_pd_gba_com_5["Enzyme Replacement Approaches"] companies_pd_gba_companies -->|"includes"| companies_pd_gba_com_5 style companies_pd_gba_com_5 fill:#81c784,stroke:#333,color:#000

...

Overview

Mermaid diagram (expand to render)

This category covers biotechnology and pharmaceutical companies developing therapeutics that target glucocerebrosidase (GBA) for Parkinson's disease treatment. GBA mutations represent the most common genetic risk factor for PD, increasing risk 5-20x and accounting for approximately 5-10% of all PD cases["@sidransky2009"]. The therapeutic approaches listed here aim to restore GBA enzyme function, reduce toxic substrate accumulation, or address the downstream effects of GBA dysfunction on alpha-synuclein pathology["@mazzulli2011"].

Key Companies

Gene Therapy Approaches

Gene therapy aims to deliver a functional GBA1 gene to restore glucocerebrosidase activity in the central nervous system. This approach offers potential for long-term disease modification.

Prevail Therapeutics (Eli Lilly)

Focus: AAV-GBA1 gene therapy for PD patients with GBA1 mutations
Lead Candidate: PR001
Indication: Parkinson's disease with GBA1 mutations
Stage: Phase 1/2 (PROVIEW trial)
Mechanism: AAV9-mediated delivery of functional GBA1 gene via intrathecal administration
Status: Acquired by Eli Lilly in 2021 for $880 million
Page: [Prevail Therapeutics](/companies/prevail-therapeutics)

Passage Bio

Focus: AAVhu68-GBA1 gene therapy
Lead Candidate: PBFT02 (IMAGINE trial)
Indication: Parkinson's disease with GBA1 mutations
Stage: Phase 1
Mechanism: Next-generation AAVhu68 capsid for enhanced CNS delivery via intra-cisterna magna administration
Page: [Passage Bio](/companies/passage-bio)

uniQure

Focus: AAV-GBA gene therapy
Lead Candidate: AMT-260 (formerly)
Indication: Parkinson's disease, GBA-associated
Stage: Phase 1
Mechanism: AAV-based gene delivery of functional GBA1
Page: [uniQure](/companies/uniqure)

Molecular Chaperone Therapy

Molecular chaperones are small molecules that stabilize mutant GBA enzymes, improving their folding, trafficking, and enzymatic activity. This approach can restore partial enzyme function.

Gain Therapeutics

Focus: Small molecule GBA modulators (therapeutic chaperones)
Lead Candidate: GT-02287
Indication: GBA1-PD (Phase 1b), idiopathic PD (Phase 1b)
Stage: Phase 1
Mechanism: Allosteric small molecule chaperone that stabilizes misfolded GCase, enhances lysosomal trafficking, and increases enzyme activity
Platform: SEE-Tx (Site-Directed Excipient Engineering)
Page: [Gain Therapeutics](/companies/gain-therapeutics)

Substrate Reduction Therapy

Substrate reduction therapy (SRT) reduces glucosylceramide accumulation by inhibiting its synthesis upstream of GBA.

Sanofi

Focus: GCS inhibitors for GBA-PD
Lead Candidates: Venglustat (GZ161), Eliglustat (Cerdelga)
Indication: GBA1-PD
Stage: Phase 2 (Venglustat completed)
Mechanism: Glucosylceramide synthase (GCS) inhibition to reduce substrate accumulation
Note: Venglustat Ivy program discontinued; Eliglustat approved for Gaucher disease
Page: [Sanofi](/companies/sanofi)

Lysosomal Enhancement Approaches

Beyond direct GBA targeting, these companies address lysosomal dysfunction through complementary mechanisms.

Lysoway Therapeutics

Focus: Lysosomal ion channel modulators (TRPML1, TMEM175 agonists)
Lead Candidates: LY-001 (TRPML1), LY-002 (TMEM175)
Indication: Parkinson's disease, Alzheimer's disease
Stage: Preclinical/Discovery
Mechanism: Small molecule agonists of lysosomal cation channels to enhance autophagy-lysosomal function through calcium signaling
Page: [Lysoway Therapeutics](/companies/lysoway-therapeutics)

INmune Bio

Focus: Enzyme modulation and neuroinflammation
Lead Candidate: XPro1595 (TNF inhibitor)
Indication: Parkinson's disease, Alzheimer's disease
Stage: Phase 2
Mechanism: Targeting neuroinflammation associated with GBA dysfunction
Page: [INmune Bio](/companies/inmune-bio)

Enzyme Replacement Approaches

Enzyme replacement therapy (ERT) involves intravenous administration of recombinant GBA. Challenges include blood-brain barrier penetration.

Existing ERT Drugs (Gaucher Disease)

| Drug | Company | Status |
|------|---------|--------|
| Taliglucerase alfa (Elelyso) | Pfizer | Approved |
| Velaglucerase alfa (VPRIV) | Takeda | Approved |
| Imiglucerase (Cerezyme) | Sanofi | Approved |

Note: These are approved for Gaucher disease but do not cross the BBB for PD treatment.

Therapeutic Approach Comparison

| Approach | Mechanism | Advantages | Challenges |
|----------|-----------|------------|------------|
| Gene Therapy (AAV-GBA) | Deliver functional GBA1 gene | Long-term expression, single administration | Invasive delivery, immune response |
| Molecular Chaperones | Stabilize mutant GBA | Oral dosing, reversible | Partial activity restoration |
| Substrate Reduction | Inhibit glucosylceramide synthesis | Well-characterized mechanism | May affect other pathways |
| Lysosomal Ion Channels | Enhance lysosomal function | Broader mechanism | Preclinical stage |
| Enzyme Replacement | Add functional enzyme | Direct enzyme replacement | Does not cross BBB |

Clinical Trial Landscape

| Trial | Company | Drug | Phase | Status |
|-------|---------|------|-------|--------|
| PROVIEW | Prevail/Lilly | PR001 | Phase 1/2 | Enrolling |
| IMAGINE | Passage Bio | PBFT02 | Phase 1 | Enrolling |
| NCT06732180 | Gain Therapeutics | GT-02287 | Phase 1b | Recruiting |
| NCT04144088 | Sanofi | Venglustat | Phase 2 | Completed |

[GBA Therapy in Parkinson's Disease](/mechanisms/gba-therapy-parkinsons)
[GBA Pathway in Parkinson's](/mechanisms/gba-pathway-parkinsons)
[GBA Glucocerebrosidase and Parkinson's](/mechanisms/gba-glucocerebrosidase-parkinsons)
[Lysosomal Function in Parkinson's](/mechanisms/gba-lysosomal-function-parkinsons)

[GBA Therapeutics Investment Landscape](/investment/gba-therapeutics)

External Links

[Michael J. Fox Foundation GBA Research](https://www.michaeljfox.org/research/)
[PD Genetics Initiative - GBA](https://www.pdgenetics.org)
[ClinicalTrials.gov - GBA Parkinson's](https://clinicaltrials.gov/search?cond=Parkinson%27s+disease&intr=GBA)

Pathway Diagram

The following diagram shows the key molecular relationships involving PD GBA Glucocerebrosidase Therapeutic Companies discovered through SciDEX knowledge graph analysis:

Mermaid diagram (expand to render)

📖 View canonical wiki page →

PD GBA Glucocerebrosidase Therapeutic Companies

Overview

Overview

Key Companies

Gene Therapy Approaches

Prevail Therapeutics (Eli Lilly)

Passage Bio

uniQure

Molecular Chaperone Therapy

Gain Therapeutics

Substrate Reduction Therapy

Sanofi

Lysosomal Enhancement Approaches

Lysoway Therapeutics

INmune Bio

Enzyme Replacement Approaches

Existing ERT Drugs (Gaucher Disease)

Therapeutic Approach Comparison

Clinical Trial Landscape

Related Mechanism Pages

Related Investment Page

See Also

External Links

Pathway Diagram